Center-Authored Papers

Filters: Author is Keefer, Michael C  [Clear All Filters]
Journal Article
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS et al..  2010.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.. The Journal of infectious diseases. 201(1):132-41. Abstract
Cheng C, Gall JGD, Nason M, King RC, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR et al..  2010.  Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8. Abstract
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC et al..  2015.  Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.. PloS one. 10(9):e0136626. Abstract
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD et al..  2013.  Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine. Abstract
Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R et al..  2017.  Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.. The Journal of infectious diseases.
Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D et al..  2010.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.. PloS one. 5(8):e11995. Abstract
Jin X, Morgan C, Yu X, De Rosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC.  2015.  Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.. Vaccine. 33(20):2347-53. Abstract
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A et al..  2011.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.. Vaccine. 29(10):1948-58. Abstract
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I et al..  2013.  Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery.. The Journal of infectious diseases. 208(5):818-29. Abstract
Spearman P, Kalams S, Elizaga M, Metch B, Chiu Y-L, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ et al..  2009.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.. Vaccine. 27(2):243-9. Abstract
Fuchs JD, Bart P-A, Frahm N, Morgan C, Gilbert PB, Kochar N, De Rosa SC, Tomaras GD, Wagner TM, Baden LR et al..  2015.  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.. Journal of AIDS & clinical research. 6(5) Abstract
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, De Rosa SC, Kalams SA, McElrath MJ et al..  2014.  Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles.. The Journal of infectious diseases. Abstract
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ et al..  2015.  Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083).. The Journal of infectious diseases. Abstract